If your business owns patents, this case shows the danger of relying too heavily on partial technical wins. NOCO could point to findings that some products would have infringed on the assumption the claims were valid, and it succeeded on several discrete issues. But because the asserted claims were ultimately found invalid and revoked, the infringement claim failed and the overall costs position turned sharply against it. Validity remains central.
If your business is defending a patent claim, the case shows the value of a well-run invalidity cross-claim. Brown and Watson won overall because invalidity succeeded. But the judgment also shows that defendants do not get a free pass on every argument they run. Abandoned prior art, unsuccessful grounds, and failed construction positions can reduce the costs recovered even where the defence wins the case overall.
The settlement aspect is also commercially important. Businesses sometimes assume that if they make a formal offer and later do better than that offer at trial, indemnity costs will follow automatically. This judgment says otherwise. The Court still asks whether the refusal was unreasonable in the circumstances at the time. Timing, the extent of compromise, the state of the evidence, and the practical value of the offer all matter.
One feature specifically noted by the Court was that Brown and Watson's January 2025 offer involved some compromise, including withdrawal of the validity challenge, no order as to costs, and payment of $200,000 to NOCO. But the Court also noted that the offer did not involve Brown and Watson ceasing to sell the impugned products. The extract available here cuts off before the full reasoning is completed, so care is needed before drawing broader conclusions from that part of the judgment. The safe point is that formal offers are powerful, but not self-executing.
For business owners and in-house teams, the practical reading is straightforward. Patent litigation should be managed as a portfolio of risks: validity risk, infringement risk, evidence risk, issue selection risk, and settlement risk. Costs exposure can remain very substantial even where you win meaningful arguments on the way through. Budgeting, board reporting, and settlement decisions should all reflect that reality.